Neil Kumar, BridgeBio CEO
May 13, 2022 07:33 AM EDT
Deals
Bioregnum

Work­ing to right the ship, Bridge­Bio's Neil Ku­mar adds a $110M deal right on top of his cash haul from Bris­tol My­ers

With­in hours of is­su­ing word that Bridge­Bio $BBIO had pulled in $90 mil­lion from its SHP2 li­cens­ing deal with Bris­tol My­ers Squibb, CEO Neil Ku­mar …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times